The Library
Pharmacological management of lewy body dementia : a systematic review and meta-analysis
Tools
Tools
Tools
Stinton, Chris, McKeith, Ian G., Taylor, John-Paul, Lafortune, Louise, Mioshi, Eneida, Mak, Elijah, Cambridge, Victoria, Mason, James, Thomas, Alan and O’Brien, John T. (2015) Pharmacological management of lewy body dementia : a systematic review and meta-analysis. American Journal of Psychiatry, 172 (8). pp. 731-742. doi:10.1176/appi.ajp.2015.14121582 ISSN 0002-953X.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1176/appi.ajp.2015.14121582
Abstract
Objective:
The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Method:
Studies were identified through bibliographic databases, trials registers, gray literature, reference lists, and experts. The authors used the search terms “Lewy or parkinson” and “dementia” through March 2015 and used the following inclusion criteria: participants with diagnoses of Lewy body dementia, dementia with Lewy bodies, or Parkinson’s disease dementia (or participants’ caregivers); investigation of pharmacological management strategies; outcome measures and test scores reported. Data extraction and quality assessment were conducted by at least two authors. Meta-analyses were conducted, and when studies could not be combined, summaries were provided.
Results:
Forty-four studies examining 22 strategies were included in the review. Meta-analysis indicated beneficial effects of donepezil and rivastigmine for cognitive and psychiatric symptoms. Rivastigmine, but not donepezil, was associated with greater risk of adverse events. Meta-analysis of memantine suggested that it is well tolerated but with few benefits. Descriptive summaries provide some evidence of benefits for galantamine, modafinil, levodopa, rotigotine, clozapine, duloxetine, clonazepam, ramelteon, gabapentin, zonisamide, and yokukansan. Piracetam, amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear to be effective.
Conclusions:
High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||
| Library of Congress Subject Headings (LCSH): | Lewy body dementia, Dementia -- Treatment, Dementia -- Psychological aspects | ||||||||
| Journal or Publication Title: | American Journal of Psychiatry | ||||||||
| Publisher: | American Psychiatric Publishing, Inc. | ||||||||
| ISSN: | 0002-953X | ||||||||
| Official Date: | 1 August 2015 | ||||||||
| Dates: |
|
||||||||
| Volume: | 172 | ||||||||
| Number: | 8 | ||||||||
| Page Range: | pp. 731-742 | ||||||||
| DOI: | 10.1176/appi.ajp.2015.14121582 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||
| Funder: | National Institute for Health Research (Great Britain) (NIHR) | ||||||||
| Grant number: | DTC-RP-PG-0311-12001 | ||||||||
| Adapted As: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
